Reports related to this article:
Project(s): View 2 related projects in PECWeb
Plant(s): View 2 related plants in PECWeb
Released February 16, 2024 | NEW DELHI
en
Researched by Industrial Info Resources (Sugar Land, Texas)--The human papillomavirus (HPV) vaccine, a preventive vaccine designed to protect against HPV infections and associated complications (like cervical cancer, anal cancer and genital warts), has received differing opinions and approaches from various regions around the world. While many countries have adopted the HPV vaccine as part of their national immunization programs, others have shown concerns about its potential side effects and long-term impacts.
Nevertheless, the demand for HPV vaccines has continued to grow in various countries, and a number of pharmaceutical companies are coming up with new investments to cater to the increasing demand.
Industrial Info is tracking 11 active capital-spending projects globally, worth US$612.31 million, aimed at the production of HPV vaccines. Nine projects are in Asia and two projects are in Europe. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for the reports.
China is the country with the biggest spending, worth US$545.11 million, and is making substantial efforts in the research and development of domestically manufactured HPV vaccines, making them more affordable and accessible to a wider population. India, Indonesia, Russia, Singapore and Thailand are also home to projects with considerable investments.
Overall, a bulk of spending is being driven by two major companies--Sinocelltech Group Limited (Beijing, China) and Jiangsu Yiming Rongyao Medical Technology Company Limited (Jiangsu, China)--with an investment of US$309.90 million and US$120 million, respectively.
Sinocelltech Group Limited's grassroot injectables fill and finish plant in Fengtai (Beijing, China) is in the engineering phase, and the plant will yield an annual production of 45 million doses of the SCT1000/14 valent HPV vaccine. Meanwhile, Yiming Rongyao Medical Technology Company Limited is planning an expansion of its vaccines fill and finish plant in Taizhou (Jiangsu, China). Subscribers can read detailed reports on the Fengtai and Taizhou projects.
Projects worth 51% of the total spending are in the engineering phase, with 13% under construction and 36% in the planning phase.
The nations actively supporting immunization continue to fortify public health resilience in the face of evolving health threats. At the same time, while controversy surrounding the HPV vaccine continues to persist, the adoption or rejection of vaccination strategies by various countries will expectedly shape the fight against emerging HPV-related diseases.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
Nevertheless, the demand for HPV vaccines has continued to grow in various countries, and a number of pharmaceutical companies are coming up with new investments to cater to the increasing demand.
Industrial Info is tracking 11 active capital-spending projects globally, worth US$612.31 million, aimed at the production of HPV vaccines. Nine projects are in Asia and two projects are in Europe. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for the reports.
China is the country with the biggest spending, worth US$545.11 million, and is making substantial efforts in the research and development of domestically manufactured HPV vaccines, making them more affordable and accessible to a wider population. India, Indonesia, Russia, Singapore and Thailand are also home to projects with considerable investments.
Overall, a bulk of spending is being driven by two major companies--Sinocelltech Group Limited (Beijing, China) and Jiangsu Yiming Rongyao Medical Technology Company Limited (Jiangsu, China)--with an investment of US$309.90 million and US$120 million, respectively.
Sinocelltech Group Limited's grassroot injectables fill and finish plant in Fengtai (Beijing, China) is in the engineering phase, and the plant will yield an annual production of 45 million doses of the SCT1000/14 valent HPV vaccine. Meanwhile, Yiming Rongyao Medical Technology Company Limited is planning an expansion of its vaccines fill and finish plant in Taizhou (Jiangsu, China). Subscribers can read detailed reports on the Fengtai and Taizhou projects.
Projects worth 51% of the total spending are in the engineering phase, with 13% under construction and 36% in the planning phase.
The nations actively supporting immunization continue to fortify public health resilience in the face of evolving health threats. At the same time, while controversy surrounding the HPV vaccine continues to persist, the adoption or rejection of vaccination strategies by various countries will expectedly shape the fight against emerging HPV-related diseases.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
